D.A. Davidson & CO. Buys 18,597 Shares of Zimmer Biomet Holdings, Inc. $ZBH

D.A. Davidson & CO. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 170.3% during the first quarter, Holdings Channel reports. The institutional investor owned 29,520 shares of the medical equipment provider’s stock after buying an additional 18,597 shares during the period. D.A. Davidson & CO.’s holdings in Zimmer Biomet were worth $2,669,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. DV Equities LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $30,000. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $31,000. Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth approximately $32,000. Finally, Grove Bank & Trust boosted its stake in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 328 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $89.69 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The stock has a market capitalization of $17.35 billion, a price-to-earnings ratio of 23.30, a price-to-earnings-growth ratio of 2.68 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company’s 50 day simple moving average is $87.37 and its 200 day simple moving average is $89.82.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Monday, July 6th. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Citigroup decreased their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Finally, Leerink Partners began coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.